8. NRx Pharmaceuticals (NASDAQ:NRXP)
NRx Pharmaceuticals comes in at No. 8 because it is exactly the type of stock that can light up biotech penny stock screens in a hurry. Trading around $4.42 with a market capitalization near $160 million, NRXP still falls into the penny-stock zone and carries the kind of small-cap profile that can attract aggressive traders looking for FDA-related developments, mental health treatment catalysts, and speculative healthcare momentum.
The near-term attention around NRX-100 and KETAFREE gives this stock its trading appeal. In biotech, a catalyst is often more powerful than a current income statement, especially for small-cap companies. Investors want to know whether a product candidate can receive regulatory traction, whether the FDA pathway is becoming clearer, and whether a treatment can address a real medical need. When those questions sit in front of a stock with a small market cap and low share price, volatility usually follows.
NRXP also reported a lower Q1 2026 net loss versus the prior year, which is a useful point for investors searching for biotech penny stocks with improving financial discipline. It does not automatically make the company financially strong, but it suggests that the story is not only about scientific hope. In a market that has become more selective with speculative biotech names, even modest improvement in losses can help support sentiment if it comes alongside regulatory or clinical progress.
Still, this is not one of the safest names on the list. It belongs here because of its ability to move, not because it has the most stable foundation. FDA-related developments can move a biotech stock aggressively, but they can also punish it quickly. One delay, one unclear regulatory update, one financing concern, or one disappointing market interpretation can erase gains fast. That is the reality of catalyst-driven biotech penny stocks.
For June, NRXP fits the SEO-friendly label investors often search for: “high-risk biotech penny stock with FDA catalyst potential.” It is not the cleanest investment case, but it has the pieces that traders usually monitor: small market cap, low share price, regulatory attention, improving net loss, and the possibility of major news flow. That combination earns it a place at No. 8, but anyone looking at this name should understand that it behaves more like a tactical trade than a conservative biotech investment.
Click next to see the following stock...
